- Home
- GAM vs TRVI Comparison
GAM vs TRVI Comparison
Compare GAM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | TRVI |
|---|---|---|
| Founded | 1927 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GAM | TRVI |
|---|---|---|
| Price | $64.98 | $14.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 29.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.41 | $5.38 |
| 52 Week High | $64.94 | $16.12 |
Technical Indicators
Market Signals| Indicator | GAM | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 76.15 | 67.43 |
| Support Level | $62.22 | $10.07 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.96 | 0.93 |
| MACD | 0.52 | 0.19 |
| Stochastic Oscillator | 88.51 | 71.88 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.